Immunome IMNM
NASDAQ IMNM
$17.99 -0.27 (-1.48%)
At close: Oct 23, 2026 · 4:00 PM EDT

Immunome (IMNM) Sale and Maturity of Investments (2024 - 2025)

Updated

Analysis

Immunome (IMNM) Sale and Maturity of Investments (2024 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Investments Sold (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn -
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 308.00 Mn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn -
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 1.30 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 136.00 Mn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn -
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn -
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn 1.03 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 2.12 Bn
10 Immunome 2.04 Bn 11.22 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 125.00 Mn
Jun 30, 2025 60.00 Mn
Mar 31, 2025 15.00 Mn
Dec 31, 2024 85.00 Mn
Sep 30, 2024 30.00 Mn
API Access

Immunome Sale and Maturity of Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=sale-and-maturity-of-investments&ticker=IMNM&period=max&api_key=YOUR_API_KEY